Nektar Therapeutics (NASDAQ:NKTR) gapped down before the market opened on Friday . The stock had previously closed at $93.74, but opened at $93.87. Nektar Therapeutics shares last traded at $93.87, with a volume of 4924815 shares trading hands.
NKTR has been the subject of a number of research reports. Jefferies Group boosted their target price on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. BidaskClub upgraded shares of Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 21st. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 21st. Cowen reiterated a “buy” rating and set a $101.00 target price on shares of Nektar Therapeutics in a research note on Friday, March 2nd. Finally, Mizuho boosted their price objective on shares of Nektar Therapeutics from $45.00 to $89.00 and gave the company a “buy” rating in a research report on Monday, January 22nd. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $63.75.
The company has a debt-to-equity ratio of 2.79, a quick ratio of 5.63 and a current ratio of 5.82. The stock has a market cap of $16,390.00, a PE ratio of -170.67 and a beta of 1.74.
In related news, COO John Nicholson sold 4,879 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $82.94, for a total value of $404,664.26. Following the completion of the transaction, the chief operating officer now owns 387,657 shares of the company’s stock, valued at approximately $32,152,271.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Stephen K. Doberstein sold 2,426 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $82.94, for a total transaction of $201,212.44. Following the completion of the transaction, the senior vice president now directly owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 369,592 shares of company stock valued at $34,241,981. Insiders own 6.10% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. bought a new position in Nektar Therapeutics in the 4th quarter worth $219,000. Certified Advisory Corp bought a new position in Nektar Therapeutics in the 4th quarter worth $148,000. Xact Kapitalforvaltning AB bought a new position in Nektar Therapeutics in the 4th quarter worth $851,000. Handelsbanken Fonder AB bought a new position in Nektar Therapeutics in the 4th quarter worth $4,121,000. Finally, Slow Capital Inc. bought a new position in Nektar Therapeutics in the 4th quarter worth $919,000. 96.22% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3336386/nektar-therapeutics-nktr-shares-gap-down-to-93-87.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.